Searchable abstracts of presentations at key conferences in endocrinology

ea0032s21.3 | Multi-centre pituitary studies | ECE2013

Lessons from the European Cushing’s registry (ERCUSYN)

Susan Webb

ERCUSYN owned by ESE, was set up in 2007 with European funding for 3 years. Sustainability has been achieved by agreements with pharma, and generous support from funding partners and Lohmann and Birkner GmBH, who established and maintained the on-line registry and web ( brochures for patients and physicians are available in different languages, as well as details on >50 participating centres ...

ea0026mte15 | (1) | ECE2011


Webb Susan

Cushing syndrome (CS) is associated with systemic complications, like central obesity, ‘moon’ face, limb atrophy, increased fat mass and reduced bone and lean body mass, excessive fatigue, purple striae, easy bruising and skin ulceration, hirsutism, hypogonadism and decreased libido. Morbidity like hypertension, insulin resistance and/or diabetes mellitus, dyslipidemia, prothrombotic state, vascular disease, atherosclerosis and increased cardiovascular risk, acquired...

ea0034n1.3 | Cushing's Syndrome | SFEBES2014

Why do cured? Cushing’s patients need long-term follow-up?

Webb Susan M

Cushing’s syndrome (CS) is associated with systemic complications, which despite successful treatment are not always totally reversible. Morbidity like venous thromboembolism, myocardial infarction, stroke, peptic ulcers, fractures and infections are higher in patients diagnosed with CS, both of adrenal and pituitary origin, and remain elevated during long-term follow-up. In fact, this increased multimorbidity risk is even present in the 3 years before diagnosis, as demon...

ea0021cm1.3 | Long-term consequences of endocrine diseases | SFEBES2009

Long term consequences of Cushing's syndrome

Webb Susan , Resmini E , Barahona M J , Santos A , Ybarra J

Endogenous hypercortisolism and chronic glucocorticoid (GC) therapy reduce bone mass, increase central fat mass, alter adipokines and enhance cardiovascular risk. Surgery (pituitary, adrenal or for ectopic ACTH) can control hypercortisolism in 90% of patients in experienced hands, and is often followed by inhibition of the adrenal axis, requiring substitution therapy with GC for months or years. We have been interested in learning on long-term outcome of ‘cured’ CS p...

ea0081oc4.5 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Real-world injection experience and use of independent injection among patients using lanreotide autogel/depot (LAN) prefilled syringe or octreotide long-acting release (OCT) to treat acromegaly or neuroendocrine tumors (NETs): international PRESTO 2 survey

Webb Susan , O'Toole Dermot , Kunz Pamela , Houchard Aude , Boiziau Sandra , Ribeiro-Oliveira Antonio , Prebtani Ally

Introduction: Long-acting (LA) somatostatin analog (SSA) therapy is a common first-line medical treatment for acromegaly and NETs. There are limited real-world data on patients’ injection experience with the latest LA SSA devices/formulations.Aims: To compare the injection experience of patients with acromegaly or NETs who were receiving treatment with LAN prefilled syringe vs OCT syringe.Methods: A 2021 e-survey of adults wit...

ea0063p729 | Pituitary and Neuroendocrinology 2 | ECE2019

Muscle dysfunction is associated with poor quality of life in patients with Cushing’s syndrome long-term after remission

Martel Luciana , Bascunana Helena , Cuartero Jordi , Biagetti Betina , Webb Susan M. , Valassi Elena

Background: Residual morbidity in patients with Cushing’s syndrome (CS) in remission significantly affects Quality of Life (QoL). While sustained muscle weakness is a frequent complaint in these patients, the impact of muscle dysfunction on their psychophysical wellbeing is currently unknown. Patients & methods: We included 28 female patients [mean(±SD) age, 50±12 years; mean (±SD) BMI, 26.7±3.8] and 26 age- and BMI-matched healthy controls. Mean (...

ea0049gp36 | Bone & Calcium Homeostasis 1 | ECE2017

Relationship between circulating microRNAs and bone mineral density in patients with active acromegaly

Valassi Elena , Garcia-Giralt Natalia , Malouf Jorge , Crespo Iris , Webb Susan M.

Objective: Acromegaly (ACRO) is associated with abnormal bone remodeling and reduced volumetric bone mineral density (vBMD) at the lumbar spine and proximal femur. Circulating microRNAs (miRNAs) modulate the activity of osteoblasts and osteoclasts, and are currently being investigated as potential biomarkers of osteoporosis. The aims of our study were: 1) To identify differentially expressed miRNAs in the serum of five patients with active ACRO vs. healthy controls, and 2) To ...

ea0041ep17 | Adrenal cortex (to include Cushing's) | ECE2016

Psychopathology, memory and quality of life in Cushing’s syndrome

Santos Alicia , Resmini Eugenia , Crespo Iris , Valassi Elena , Martinez Maria Antonia , Pires Patricia , Webb Susan

Introduction: Cushing’s syndrome (CS) has been related to higher psychopathology. Psychopathology can be related to poor memory performance, and low quality of life. The aim of this study is to establish the relationship between the three parameters and with subjective symptom perception in CS.Methods/design: Thirty six patients in remission of CS and 36 matched controls for age, sex and education years were included in the study. They completed SCL...

ea0037gp.02.06 | Adrenal (1) | ECE2015

DNA methylation of FKBP5 and its relationship with hippocampal volumes in Cushing's syndrome patients

Resmini Eugenia , Santos Alicia , Aulinas Anna , Webb Susan , Gomez-Anson Beatriz , Cox Olivia , Lee Richard

Introduction: FKBP5 is a protein that regulates glucocorticoid receptor sensitivity, via an ultra-short negative feedback mechanism. Variations in the FKBP5 gene can influence the response to glucocorticoids (GC). Hypercortisolaemia plays a role on impairment of brain function and could be mediated by epigenetic variations of the FKBP5 gene. Cushing’s syndrome (CS), a disease characterized by hypercortisolaemia, is associated with memory deficits, lower ...

ea0037gp.19.03 | Pituitary–Acromegaly | ECE2015

Perceived quality of life in acromegaly: results from a tertiary UK centre

Kyriakakis Nikolaos , Lynch Julie , Gilbey Stephen G , Webb Susan M , Murray Robert D

Introduction: Patients with acromegaly are frequently left with long-term adverse sequelae. When compared with individuals with other pituitary adenomas, patients with acromegaly demonstrate greater impairment in their quality of life (QoL).Methods: The disease-specific questionnaire, AcroQoL, and the generic psychological general well-being schedule (PGWBS) were used to evaluate QoL in an acromegaly patient cohort. Longitudinal data were also collected ...